Update shared on 08 Nov 2025
Fair value Decreased 5.54%Analysts have revised Piramal Pharma's fair value estimate down from ₹258.67 to ₹244.33 per share. This change reflects updated assumptions about revenue growth and profit margins.
What's in the News
- Piramal Pharma Solutions has signed a Memorandum of Understanding with IntoCell Inc., forming a strategic partnership to develop antibody-drug conjugates (ADC) and expand licensing opportunities for proprietary drug-linker technologies. (Key Developments)
- This collaboration enables Piramal to offer broader payload-linker options and shorter development timelines for bioconjugates, which enhances its specialized service offerings in the sector. (Key Developments)
- A board meeting is scheduled for November 5, 2025, to consider and approve the company's unaudited financial results for the quarter and half year ending September 30, 2025. (Key Developments)
Valuation Changes
- The Fair Value Estimate has decreased from ₹258.67 to ₹244.33 per share, reflecting a modest downward revision.
- The Discount Rate has risen slightly from 12.73% to 12.76%.
- The Revenue Growth projection has increased from 13.39% to 14.41%.
- The Net Profit Margin expectation has improved from 8.76% to 9.52%.
- The Future P/E Ratio has fallen from 41.09x to 35.70x, indicating a lower expected valuation multiple.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.